AxoGen, Inc. to Report Third Quarter 2017 Financial Results and Host Conference Call on November 1, 2017
October 17 2017 - 7:00AM
AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and
marketing innovative surgical solutions for the repair of
peripheral nerve damage, today announced that it will report third
quarter 2017 financial results on Wednesday, November 1, 2017 after
the market closes. AxoGen management will host an
investment-community conference call and webcast following the
release at 4:30 p.m. ET to discuss the financial results and
provide a corporate update.
Investors interested in participating in the
conference call by phone may do so by dialing toll free at (877)
407-0993, or use the direct dial-in number at (201) 689-8795. Those
interested in listening to the conference call live via the
Internet may do so by visiting
http://axogeninc.equisolvewebcast.com/q1-2017.
Following the conference call, a replay will be
available in the Investors section of the company's website at
www.axogeninc.com.
About AxoGenAxoGen (AXGN) is a
global leader in innovative surgical solutions for peripheral nerve
injuries. AxoGen is the leading company focused specifically on the
science, development and commercialization of technologies for
peripheral nerve regeneration and repair. We are passionate about
restoring nerve function and quality of life to patients with
peripheral nerve injuries by providing innovative, clinically
proven and economically effective repair solutions for surgeons and
health care providers. Peripheral nerves provide the pathways for
both motor and sensory signals throughout the body. Every day,
people suffer traumatic injuries or undergo surgical procedures
that impact the function of their peripheral nerves. Damage to
a peripheral nerve can result in the loss of muscle or organ
function, the loss of sensory feeling, or the initiation of
pain.
AxoGen's platform for nerve repair features a
comprehensive portfolio of products, including Avance® Nerve Graft,
an off-the-shelf processed human nerve allograft for bridging
severed nerves without the comorbidities associated with a second
surgical site, AxoGuard® Nerve Connector, a porcine submucosa
extracellular matrix (ECM) coaptation aid for tensionless repair of
severed nerves, AxoGuard® Nerve Protector, a porcine submucosa ECM
product used to wrap and protect injured peripheral nerves and
reinforce the nerve reconstruction while preventing soft tissue
attachments, and Avive® Soft Tissue Membrane, a minimally
processed human umbilical cord membrane that may be used as a
resorbable soft tissue covering to separate tissue layers and
modulate inflammation in the surgical bed. Along with these core
surgical products, AxoGen also offers AcroVal® Neurosensory &
Motor Testing System and AxoTouch® Two-Point Discriminator. These
evaluation and measurement tools assist health care professionals
in detecting changes in sensation, assessing return of sensory,
grip, and pinch function, evaluating effective treatment
interventions, and providing feedback to patients on nerve
function. The AxoGen portfolio of products is available in the
United States, Canada, the United Kingdom, and several other
European and international countries.
Cautionary Statements Concerning
Forward-Looking Statements This Press Release contains
"forward-looking" statements as defined in the Private Securities
Litigation Reform Act of 1995. These statements are based on
management's current expectations or predictions of future
conditions, events, or results based on various assumptions and
management's estimates of trends and economic factors in the
markets in which we are active, as well as our business plans.
Words such as "expects," "anticipates," "intends," "plans,"
"believes," "seeks," "estimates," "projects," "forecasts,"
"continue," "may," "should," "will," and variations of such words
and similar expressions are intended to identify such
forward-looking statements. The forward-looking statements may
include, without limitation, statements regarding our assessment on
our internal control over financial reporting, our growth, our 2017
guidance, product development, product potential, financial
performance, sales growth, product adoption, market awareness of
our products, data validation, our visibility at and sponsorship of
conferences and educational events. The forward-looking statements
are subject to risks and uncertainties, which may cause results to
differ materially from those set forth in the statements.
Forward-looking statements in this release should be evaluated
together with the many uncertainties that affect AxoGen's business
and its market, particularly those discussed in the risk factors
and cautionary statements in AxoGen's filings with the Securities
and Exchange Commission. Forward-looking statements are not
guarantees of future performance, and actual results may differ
materially from those projected. The forward-looking statements are
representative only as of the date they are made and, except as
required by law, AxoGen assumes no responsibility to update any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contacts:AxoGen, Inc.Peter J. Mariani, Chief
Financial OfficerInvestorRelations@AxoGenInc.com
The Trout Group – Investor RelationsBrian
Korb646.378.2923bkorb@troutgroup.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Apr 2023 to Apr 2024